Published on : Sep 03, 2014
Novo Nordisk has chosen Mexico as its next target country for launching its new combo diabetes treatment, Ryzodeg. In early 2014, this company had declared that it would be launching its obesity-tackling formula involving liraglutide in Mexico. Ryzodeg is a combination of Novo’s Novolog, which is a fast acting insulin aspart and Tresiba, which is Novo’s long acting treatment. The delivery of these two drugs is done via a combination injector.
According to Novo, this combination is its first unique amalgam of mealtime insulin and long acting basal insulin in a single pen.
Europe has given its approval for launching Tresiba and its combination partner, however, Ryzodeg has not yet been launched by Novo. US is yet to give its approval to both these medicines and as a result, Novo has been asked to conduct a safety study on Tresiba.
With almost 8.7 million Mexicans living with diabetes, there is a huge market potential for Novo and many other diabetes drug manufacturers. Obesity is a major problem in Mexico with almost 7 out of 10 Mexicans being overweight and one third of the adult population being obese. In fact, Mexico was declared as the fattest country in the world last year. This is one of the driving factors for Novo to launch its obesity fighting drug here.
This drug will be available in the Mexican market in early 2015, as soon as it gets its approval from the US.
Currently, the company is focusing mainly on conducting the safety study of Tresiba in order to acquire FDA approval. In the month of August, Novo had stated that it was ahead of its schedule on the Tresiba study.